McGuinness, Julia E. http://orcid.org/0000-0001-5292-1440
Altoe, Mirella L.
Marone, Alessandro
Franks, Lauren E.
Lee, Shing M.
Kim, Hyun K.
Tejada, Mariella
Trivedi, Meghna S.
Accordino, Melissa K.
Crew, Katherine D.
Hershman, Dawn L.
Hielscher, Andreas H.
Kalinsky, Kevin
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR001873)
Article History
Received: 29 March 2021
Accepted: 26 June 2021
First Online: 2 July 2021
Declarations
:
: JEM, MLA, AM, LEF, SL, HKK, MT, MST, MKA, KDC, DLH, AHH declare no conflict of interest. KK declares the following potential conflicts of interest: <i>Medical Advisor</i>—Immunomedics, Pfizer, Novartis, Eisai, Eli-Lilly, Amgen, Immunomedics, Merck, Seattle Genetics, and Astra Zeneca; <i>Institutional Support</i>—Immunomedics, Novartis, Incyte, Genentech/Roche, Eli-Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zentalis Pharmaceuticals, and CytomX Therapeutics; <i>Speakers Bureau</i>—Eli-Lilly; <i>Spouse</i>—Array Biopharma, Pfizer, Grail.
: The institutional review board at Columbia University Irving Medical Center approved the study protocol (AAAI9154).
: Informed consent was obtained from all patients prior to their enrollment.